These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9065544)

  • 1. Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
    Turkka J; Suominen K; Tolonen U; Sotaniemi K; Myllylä VV
    Neurology; 1997 Mar; 48(3):662-7. PubMed ID: 9065544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.
    Haapaniemi TH; Kallio MA; Korpelainen JT; Suominen K; Tolonen U; Sotaniemi KA; Myllylä VV
    J Neurol; 2000 Nov; 247(11):868-74. PubMed ID: 11151420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of orthostatic hypotension in Parkinson's disease.
    Oka H; Yoshioka M; Onouchi K; Morita M; Mochio S; Suzuki M; Hirai T; Ito Y; Inoue K
    Brain; 2007 Sep; 130(Pt 9):2425-32. PubMed ID: 17673498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
    Churchyard A; Mathias CJ; Lees AJ
    Mov Disord; 1999 Mar; 14(2):246-51. PubMed ID: 10091617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
    Bhattacharya KF; Nouri S; Olanow CW; Yahr MD; Kaufmann H
    Parkinsonism Relat Disord; 2003 Mar; 9(4):221-4. PubMed ID: 12618057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline and blood pressure in patients with Parkinson's disease.
    Pursiainen V; Korpelainen TJ; Haapaniemi HT; Sotaniemi AK; Myllylä VV
    Acta Neurol Scand; 2007 Feb; 115(2):104-8. PubMed ID: 17212613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
    Olanow CW
    J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients.
    Camerlingo M; Ferraro B; Gazzaniga GC; Casto L; Cesana BM; Mamoli A
    Acta Neurol Scand; 1990 Apr; 81(4):346-8. PubMed ID: 2360402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Heinonen E; Myllylä V
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
    [No Abstract]   [Full Text] [Related]  

  • 15. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Coyle J; Hobson P; Meara J
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
    [No Abstract]   [Full Text] [Related]  

  • 16. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-hour ambulatory blood pressure and heart rate profiles in diagnosing orthostatic hypotension in Parkinson's disease and multiple system atrophy.
    Vichayanrat E; Low DA; Iodice V; Stuebner E; Hagen EM; Mathias CJ
    Eur J Neurol; 2017 Jan; 24(1):90-97. PubMed ID: 27718292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular reflexes in Parkinson's disease.
    Turkka JT; Tolonen U; Myllylä VV
    Eur Neurol; 1987; 26(2):104-12. PubMed ID: 3830206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction.
    Holmberg B; Corneliusson O; Elam M
    Mov Disord; 2005 Aug; 20(8):976-81. PubMed ID: 15858814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.